Cardiac rhabdomyoma
diseaseOn this page
Also known as cardiac rhabdomyoma (disease)heart rhabdomyomarhabdomyoma of heartrhabdomyoma of the heart
Summary
Cardiac rhabdomyoma (MONDO:0006123) is a disease with 1 cohort gene and 1 clinical trial.
At a glance
- Cohort genes: 1
- ClinVar variants: 1
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cardiac rhabdomyoma |
| Mondo ID | MONDO:0006123 |
| EFO | EFO:1000150 |
| NCIT | C6739 |
| UMLS | C1332852 |
| MedGen | 232027 |
| GARD | 0027742 |
| Anatomy (UBERON) | UBERON:0000948 |
| Is cancer (heuristic) | no |
Also known as: cardiac rhabdomyoma · cardiac rhabdomyoma (disease) · heart rhabdomyoma · rhabdomyoma of heart · rhabdomyoma of the heart
Data availability: 1 ClinVar variant · 1 HPO phenotype.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › cardiovascular organ benign neoplasm › benign neoplasm of heart › cardiac rhabdomyoma
Related subtypes (4): heart lipoma, benign neoplasm of endocardium, benign neoplasm of epicardium, benign neoplasm of myocardium
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
1 retrieved; paginated sample, class counts are floors:
1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 48943 | NM_000368.5(TSC1):c.2356C>T (p.Arg786Ter) | TSC1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| TSC1 | Orphanet:210159 | Adult hepatocellular carcinoma |
| TSC1 | Orphanet:269008 | Isolated focal cortical dysplasia type IIb |
| TSC1 | Orphanet:538 | Lymphangioleiomyomatosis |
| TSC1 | Orphanet:805 | Tuberous sclerosis complex |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| TSC1 | HGNC:12362 | ENSG00000165699 | Q92574 | Hamartin | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| TSC1 | Hamartin | Non-catalytic component of the TSC-TBC complex, a multiprotein complex that acts as a negative regulator of the canonical mTORC1 complex, an evolutionarily conserved central nutrient sensor that stimulates anabolic reactions and macromolec… |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| TSC1 | Other/Unknown | no | Hamartin |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| gluteal muscle | 1 |
| lateral globus pallidus | 1 |
| substantia nigra pars compacta | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| TSC1 | 297 | ubiquitous | marker | substantia nigra pars compacta, gluteal muscle, lateral globus pallidus |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| TSC1 | 5,445 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TSC1 | Q92574 | 5 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Inhibition of TSC complex formation by AKT (PKB) | 1 | 2284.0× | 0.002 | TSC1 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 1 | 393.8× | 0.006 | TSC1 |
| TBC/RABGAPs | 1 | 259.6× | 0.006 | TSC1 |
| TP53 Regulates Metabolic Genes | 1 | 129.8× | 0.009 | TSC1 |
| Macroautophagy | 1 | 115.3× | 0.009 | TSC1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| memory T cell differentiation | 1 | 5617.3× | 0.004 | TSC1 |
| cellular response to decreased oxygen levels | 1 | 4213.0× | 0.004 | TSC1 |
| negative regulation of ATP-dependent activity | 1 | 1685.2× | 0.004 | TSC1 |
| negative regulation of cell size | 1 | 1685.2× | 0.004 | TSC1 |
| regulation of cell-matrix adhesion | 1 | 1296.3× | 0.004 | TSC1 |
| negative regulation of macroautophagy | 1 | 1123.5× | 0.004 | TSC1 |
| regulation of stress fiber assembly | 1 | 991.3× | 0.004 | TSC1 |
| obsolete D-glucose import | 1 | 842.6× | 0.004 | TSC1 |
| activation of GTPase activity | 1 | 732.7× | 0.004 | TSC1 |
| cardiac muscle cell differentiation | 1 | 674.1× | 0.004 | TSC1 |
| positive regulation of focal adhesion assembly | 1 | 648.1× | 0.004 | TSC1 |
| negative regulation of TOR signaling | 1 | 561.7× | 0.005 | TSC1 |
| associative learning | 1 | 481.5× | 0.005 | TSC1 |
| cell projection organization | 1 | 374.5× | 0.006 | TSC1 |
| negative regulation of TORC1 signaling | 1 | 324.1× | 0.006 | TSC1 |
| adult locomotory behavior | 1 | 300.9× | 0.006 | TSC1 |
| synapse organization | 1 | 280.9× | 0.006 | TSC1 |
| myelination | 1 | 251.5× | 0.007 | TSC1 |
| hippocampus development | 1 | 230.8× | 0.007 | TSC1 |
| response to insulin | 1 | 230.8× | 0.007 | TSC1 |
| cerebral cortex development | 1 | 205.5× | 0.007 | TSC1 |
| cellular response to starvation | 1 | 193.7× | 0.007 | TSC1 |
| potassium ion transport | 1 | 191.5× | 0.007 | TSC1 |
| neural tube closure | 1 | 187.2× | 0.007 | TSC1 |
| cell-matrix adhesion | 1 | 163.6× | 0.008 | TSC1 |
| kidney development | 1 | 140.4× | 0.008 | TSC1 |
| cell population proliferation | 1 | 102.8× | 0.011 | TSC1 |
| adaptive immune response | 1 | 84.3× | 0.013 | TSC1 |
| regulation of cell cycle | 1 | 74.6× | 0.014 | TSC1 |
| protein stabilization | 1 | 66.9× | 0.015 | TSC1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| TSC1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | TSC1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| TSC1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02654340 | Not specified | TERMINATED | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) |
Related Atlas pages
- Cohort genes: TSC1